Tokyo Tape
Sign in
← ASKA Pharmaceutical Holdings

Annual report

4886.TEDINET S100TOTO
Period2023-04-01 → 2024-03-31
Filed2024-06-25
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 96
MetricValuePeriodScopeSource row
Revenue¥62.8bn2023-04-01 → 2024-03-31Cons.Net sales
Revenue¥60.5bn2022-04-01 → 2023-03-31Cons.Net sales
Revenue¥56.6bn2021-04-01 → 2022-03-31dCons.Net sales (5-year summary)
Operating income¥6.5bn2023-04-01 → 2024-03-31Cons.Operating income
Operating income¥5.1bn2022-04-01 → 2023-03-31Cons.Operating income
Ordinary income¥6.5bn2023-04-01 → 2024-03-31Cons.Ordinary income
Ordinary income¥5.2bn2022-04-01 → 2023-03-31Cons.Ordinary income
Ordinary income¥4.9bn2021-04-01 → 2022-03-31dCons.Ordinary income loss (5-year summary)
Profit before tax¥9.9bn2023-04-01 → 2024-03-31Cons.Income before income taxes
Profit before tax¥5.4bn2022-04-01 → 2023-03-31Cons.Income before income taxes
Net income (owners)¥7.5bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.2bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.3bn2021-04-01 → 2022-03-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income¥7.5bn2023-04-01 → 2024-03-31Cons.Profit loss
Net income¥4.2bn2022-04-01 → 2023-03-31Cons.Profit loss
Total assets¥90.7bnat 2024-03-31Cons.Assets
Total assets¥87.1bnat 2023-03-31Cons.Assets
Total assets¥83.3bnat 2022-03-31dCons.Total assets (5-year summary)
Total liabilities¥28.8bnat 2024-03-31Cons.Liabilities
Total liabilities¥32.6bnat 2023-03-31Cons.Liabilities
Net assets / equity¥61.9bnat 2024-03-31Cons.Net assets
Net assets / equity¥54.5bnat 2023-03-31Cons.Net assets
Net assets / equity¥48.9bnat 2022-03-31dCons.Net assets
Cash and deposits¥13.7bnat 2024-03-31Cons.Cash and deposits
Cash and deposits¥14.5bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥16.7bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥17.5bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥17.1bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥1.5bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities
Operating cash flow¥3.4bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities
Operating cash flow¥2.8bn2021-04-01 → 2022-03-31dCons.Net cash provided by used in operating activities (5-year summary)
Investing cash flow¥1.7bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥1.1bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investment activities
Investing cash flow¥6.7bn2021-04-01 → 2022-03-31dCons.Net cash provided by used in investing activities (5-year summary)
Financing cash flow−¥3.9bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥1.8bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥3.0bn2021-04-01 → 2022-03-31dCons.Net cash provided by used in financing activities (5-year summary)
EPS (basic)¥266.512023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥150.082022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥151.222021-04-01 → 2022-03-31dCons.Basic earnings loss per share (5-year summary)
Net assets per share¥2,186.1at 2024-03-31Cons.Net assets per share (5-year summary)
Net assets per share¥1,928.14at 2023-03-31Cons.Net assets per share (5-year summary)
Net assets per share¥1,734.8at 2022-03-31dCons.Net assets per share (5-year summary)
Equity ratio68.3%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio62.6%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio58.7%at 2022-03-31dCons.Equity to asset ratio (5-year summary)
ROE13.0%2023-04-01 → 2024-03-31Cons.Rate of return on equity (5-year summary)
ROE8.2%2022-04-01 → 2023-03-31Cons.Rate of return on equity (5-year summary)
ROE8.8%2021-04-01 → 2022-03-31dCons.Rate of return on equity (5-year summary)
Employees762at 2024-03-31Cons.Number of employees
Employees747at 2023-03-31Cons.Number of employees
Employees777at 2022-03-31dCons.Number of employees
Revenue¥3.7bn2023-04-01 → 2024-03-31StandaloneOperating revenue1
Revenue¥1.7bn2022-04-01 → 2023-03-31StandaloneOperating revenue1
Revenue¥1.4bn2021-04-01 → 2022-03-31dStandaloneOperating revenue1 (5-year summary)
Operating income¥2.5bn2023-04-01 → 2024-03-31StandaloneOperating income
Operating income¥658m2022-04-01 → 2023-03-31StandaloneOperating income
Ordinary income¥2.5bn2023-04-01 → 2024-03-31StandaloneOrdinary income
Ordinary income¥603m2022-04-01 → 2023-03-31StandaloneOrdinary income
Ordinary income¥717m2021-04-01 → 2022-03-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax¥2.5bn2023-04-01 → 2024-03-31StandaloneIncome before income taxes
Profit before tax¥603m2022-04-01 → 2023-03-31StandaloneIncome before income taxes
Net income¥2.5bn2023-04-01 → 2024-03-31StandaloneProfit loss
Net income¥591m2022-04-01 → 2023-03-31StandaloneProfit loss
Net income¥682m2021-04-01 → 2022-03-31dStandaloneNet income loss (5-year summary)
Total assets¥43.2bnat 2024-03-31StandaloneAssets
Total assets¥41.6bnat 2023-03-31StandaloneAssets
Total assets¥41.3bnat 2022-03-31dStandaloneTotal assets (5-year summary)
Total liabilities¥565mat 2024-03-31StandaloneLiabilities
Total liabilities¥630mat 2023-03-31StandaloneLiabilities
Net assets / equity¥42.7bnat 2024-03-31StandaloneNet assets
Net assets / equity¥40.9bnat 2023-03-31StandaloneNet assets
Net assets / equity¥40.7bnat 2022-03-31dStandaloneNet assets
Cash and deposits¥2.2bnat 2024-03-31StandaloneCash and deposits
Cash and deposits¥1.1bnat 2023-03-31StandaloneCash and deposits
EPS (basic)¥87.12023-04-01 → 2024-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥20.952022-04-01 → 2023-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥23.792021-04-01 → 2022-03-31dStandaloneBasic earnings loss per share (5-year summary)
Dividend per share¥402023-04-01 → 2024-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥162022-04-01 → 2023-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥152021-04-01 → 2022-03-31dStandaloneDividend paid per share (5-year summary)
Net assets per share¥1,506.47at 2024-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥1,447.55at 2023-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥1,443.94at 2022-03-31dStandaloneNet assets per share (5-year summary)
Equity ratio98.7%at 2024-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio98.5%at 2023-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio98.5%at 2022-03-31dStandaloneEquity to asset ratio (5-year summary)
ROE5.9%2023-04-01 → 2024-03-31StandaloneRate of return on equity (5-year summary)
ROE1.5%2022-04-01 → 2023-03-31StandaloneRate of return on equity (5-year summary)
ROE1.7%2021-04-01 → 2022-03-31dStandaloneRate of return on equity (5-year summary)
Shares issued30,563,199at 2024-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued30,563,199at 2023-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued30,563,199at 2022-03-31dStandaloneTotal number of issued shares (5-year summary)
Employees75at 2024-03-31StandaloneNumber of employees
Employees79at 2023-03-31StandaloneNumber of employees
Employees74at 2022-03-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 55
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsemployeesat 2024-03-3115 pure
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2024-03-31¥226m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2024-03-31¥162m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2024-03-31¥64m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment assetsat 2024-03-31¥39m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2024-03-31−¥125m
Reconciling Itemsreconcilingdepreciation2023-04-01 → 2024-03-31¥201m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2024-03-31−¥64m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2024-03-31−¥64m
Reconciling Itemsreconcilingsegment assetsat 2024-03-31¥42.2bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2024-03-31−¥1.2bn
Animal Health Businessreportable segmentdepreciation2023-04-01 → 2024-03-31¥4m
Animal Health Businessreportable segmentemployeesat 2024-03-3134 pure
Animal Health Businessreportable segmentrevenue2023-04-01 → 2024-03-31¥6.7bn
Animal Health Businessreportable segmentrevenue external2023-04-01 → 2024-03-31¥6.7bn
Animal Health Businessreportable segmentsegment assetsat 2024-03-31¥3.5bn
Animal Health Businessreportable segmentsegment profit2023-04-01 → 2024-03-31¥195m
Pharmaceutical Businessreportable segmentdepreciation2023-04-01 → 2024-03-31¥2.2bn
Pharmaceutical Businessreportable segmentemployeesat 2024-03-31627 pure
Pharmaceutical Businessreportable segmentrevenue2023-04-01 → 2024-03-31¥56.0bn
Pharmaceutical Businessreportable segmentrevenue external2023-04-01 → 2024-03-31¥56.0bn
Pharmaceutical Businessreportable segmentsegment assetsat 2024-03-31¥45.0bn
Pharmaceutical Businessreportable segmentsegment profit2023-04-01 → 2024-03-31¥7.6bn
Total Of Reportable Segments And Otherssegment totaldepreciation2023-04-01 → 2024-03-31¥2.2bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2024-03-31¥62.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2024-03-31¥62.8bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2024-03-31¥64m
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2024-03-31¥48.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2024-03-31¥7.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2023-03-31¥298m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2023-03-31¥220m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2023-03-31¥77m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment assetsat 2023-03-31¥42m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2023-03-31−¥6m
Reconciling Itemsreconcilingdepreciation2022-04-01 → 2023-03-31¥481m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2023-03-31−¥77m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2023-03-31−¥77m
Reconciling Itemsreconcilingsegment assetsat 2023-03-31¥43.9bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2023-03-31−¥1.1bn
Animal Health Businessreportable segmentdepreciation2022-04-01 → 2023-03-31¥4m
Animal Health Businessreportable segmentrevenue2022-04-01 → 2023-03-31¥6.7bn
Animal Health Businessreportable segmentrevenue external2022-04-01 → 2023-03-31¥6.7bn
Animal Health Businessreportable segmentsegment assetsat 2023-03-31¥3.0bn
Animal Health Businessreportable segmentsegment profit2022-04-01 → 2023-03-31¥409m
Pharmaceutical Businessreportable segmentdepreciation2022-04-01 → 2023-03-31¥2.5bn
Pharmaceutical Businessreportable segmentrevenue2022-04-01 → 2023-03-31¥53.6bn
Pharmaceutical Businessreportable segmentrevenue external2022-04-01 → 2023-03-31¥53.6bn
Pharmaceutical Businessreportable segmentsegment assetsat 2023-03-31¥40.1bn
Pharmaceutical Businessreportable segmentsegment profit2022-04-01 → 2023-03-31¥5.8bn
Total Of Reportable Segments And Otherssegment totaldepreciation2022-04-01 → 2023-03-31¥2.5bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2023-03-31¥60.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2023-03-31¥60.5bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2023-03-31¥77m
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2023-03-31¥43.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2023-03-31¥6.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,450
ItemContextValueUnit
Construction in progressPrior1YearInstant389000000JPY
Construction in progressCurrentYearInstant1101000000JPY
Other ppePrior1YearInstant3636000000JPY
Other ppeCurrentYearInstant3762000000JPY
Accumulated depreciation other ppePrior1YearInstant-3208000000JPY
Accumulated depreciation other ppeCurrentYearInstant-3283000000JPY
Other net ppePrior1YearInstant428000000JPY
Other net ppeCurrentYearInstant479000000JPY
Property plant and equipmentPrior1YearInstant10796000000JPY
Property plant and equipmentCurrentYearInstant11263000000JPY
Distributorship iaPrior1YearInstant3673000000JPY
Distributorship iaCurrentYearInstant2110000000JPY
Other iaPrior1YearInstant791000000JPY
Other iaCurrentYearInstant766000000JPY
Intangible assetsPrior1YearInstant4465000000JPY
Intangible assetsCurrentYearInstant2877000000JPY
Investment securitiesPrior1YearInstant14385000000JPY
Investment securitiesCurrentYearInstant15654000000JPY
Deferred tax assetsPrior1YearInstant1717000000JPY
Deferred tax assetsCurrentYearInstant2696000000JPY
Other ioaPrior1YearInstant2031000000JPY
Other ioaCurrentYearInstant2127000000JPY
Allowance for doubtful accounts ioa by groupPrior1YearInstant-17000000JPY
Allowance for doubtful accounts ioa by groupCurrentYearInstant-17000000JPY
Investments and other assetsPrior1YearInstant18117000000JPY
Investments and other assetsCurrentYearInstant20461000000JPY
Noncurrent assetsPrior1YearInstant33378000000JPY
Noncurrent assetsCurrentYearInstant34601000000JPY
AssetsPrior1YearInstant87138000000JPY
AssetsCurrentYearInstant90745000000JPY
Accounts payable tradePrior1YearInstant2838000000JPY
Accounts payable tradeCurrentYearInstant4060000000JPY
Electronically recorded obligations operating clPrior1YearInstant3022000000JPY
Electronically recorded obligations operating clCurrentYearInstant3295000000JPY
Short term loans payablePrior1YearInstant300000000JPY
Short term loans payableCurrentYearInstant300000000JPY
Current portion of long term loans payablePrior1YearInstant3138000000JPY
Current portion of long term loans payableCurrentYearInstant4680000000JPY
Accounts payable otherPrior1YearInstant4947000000JPY
Accounts payable otherCurrentYearInstant5794000000JPY
Income taxes payablePrior1YearInstant736000000JPY
Income taxes payableCurrentYearInstant2896000000JPY
Provision for bonusesPrior1YearInstant1142000000JPY
Provision for bonusesCurrentYearInstant1151000000JPY
Provision for directors bonusesPrior1YearInstant24000000JPY
Provision for directors bonusesCurrentYearInstant74000000JPY
Other clPrior1YearInstant1498000000JPY
Other clCurrentYearInstant1715000000JPY
Current liabilitiesPrior1YearInstant17650000000JPY
Current liabilitiesCurrentYearInstant23968000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 24 of 24 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2024-03-31pass
balance sheet identitynon_consolidated 2023-03-31pass rounding
balance sheet identitynon_consolidated 2024-03-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsnon_consolidated 2022-03-31pass
statement vs summary · net assetsnon_consolidated 2023-03-31pass
statement vs summary · net assetsnon_consolidated 2024-03-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2024-03-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2023-03-31pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2024-03-31pass
statement vs summary · revenueconsolidated 2022-04-01/2023-03-31pass
statement vs summary · revenueconsolidated 2023-04-01/2024-03-31pass
statement vs summary · revenuenon_consolidated 2022-04-01/2023-03-31pass
statement vs summary · revenuenon_consolidated 2023-04-01/2024-03-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsnon_consolidated 2023-03-31pass
statement vs summary · total assetsnon_consolidated 2024-03-31pass